Olaparib induces tumour response as single agent in BRCA-deficient breast cancer

Bookmark and Share
Published: 3 Jul 2009
Views: 15212
Dr Andrew Tutt - Breakthrough Breast Cancer Research Unit, Kings College London, UK
Andrew Tutt, MB, ChB, PhD, Kings College London, United Kingdom, speaking at ASCO 2009: PARP Inhibitor Olaparib Induces Tumor Response as Single Agent in BRCA-Deficient Breast Cancer: A small, Phase II international multi-center study reports that more than a third of women with BRCA1 or BRCA2 mutations and advanced breast cancer that persisted despite prior treatment experienced tumour shrinkage after receiving the investigational PARP inhibitor olaparib.